Affidea acquires Uroviva Group and doubles its presence in Switzerland

Niederer Kraft Frey advised Affidea on the acquisition of Uroviva Group.

Through this acquisition, Affidea almost doubles in size – from 17 to 33 centres and from 450 to 700 employees, positioning Affidea among the top outpatient healthcare providers in Switzerland.

This acquisition complements Affidea’s out of hospital diagnostic services and strong breast cancer care pathway, enabling the development of an adjacent prostate cancer pathway. It also opens significant synergies in pathology, diagnostic imaging and oncology. These complementary services allow Affidea to offer an integrated pathway in both breast and prostate cancer care, delivering seamless and connected care experiences for patients.

The Uroviva Group is a leading network of medical specialists, combining top-level expertise in urology, gynaecology, and oncology. With 16 locations across the cantons of Zurich, Lucerne, Zug, Solothurn, and Aargau, and approximately 250 employees – including 55 physicians – Uroviva provides excellent, comprehensive outpatient care as well as inpatient treatment where required. Its service offering includes state-of-the-art treatment methods such as the Da Vinci® Surgical System, High-Intensity Focused Ultrasound (HIFU), and Rezum™ therapy.

The NKF team was led by Corporate/M&A partner Philippe Weber, Corporate/M&A senior associate Samuel Hochstrasser and Healthcare/Regulatory partner Janine Reudt-Demont, working with associate Pascal Hodel, junior associates Peter-Conradin Schreiber, Philipp Theiler and Matthias Zinniker (all Corporate/M&A), associate Benedikt Hadorn (Finance/M&A), associate Yannik Bleiker (Real Estate), associate Stephanie Huchler (Employment) and junior associate Lukas Christen (Healthcare/Regulatory).

For German law matters NKF worked together with a team from Friedrich Graf von Westphalen Partner (FGVW) in Freiburg led by Jan Henning Martens working with Tina Bieniek.